Both malignant and non-malignant blood and bone marrow diseases can be treated with allogeneic hematopoietic cell transplantation (HCT), but the procedure is not without its risks of complications, including the potential for acute or chronic graft-versus-host disease (GVHD). What strategies can be used to recognize symptoms and best manage patients after allogeneic HCT? Our host, Dr. Dennis Kim, takes a deep look into this topic with Dr. Mahmoud Elsawy, Hematologist with the Nova Scotia Health Authority and Clinical Assistant Professor at Dalhousie University.

This episode discusses the early- and late-term complications associated with allogeneic HCT and the importance of intervening early and effectively, especially with harder-t ...